Darron R. Brown, Department of Medicine, Indiana University School of Medicine, Van Nuys Med Science Building, Suite 224, 635 Barnhill Drive, Indianapolis, IN, 46202, USA. Electronic address: darbrow@iu.edu
Xavier Castellsagué, Institut Catala d'Oncologia, IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Granvia de l'Hospitalet 199-203, Barcelona, Catalonia, 08908, Spain
Daron Ferris, Clinica CerviCusco, Calle Los Saucos B-8-2, Larapa, Curco, Peru
Suzanne M. Garland, Centre for Women's Infectious Diseases, The Royal Women's Hospital, Infection and Immunity, Murdoch Children's Research Institute, Department of Obstetrics and Gynaecology, The University of Melbourne, Murdoch Children's Research Institute, The Royal Women's Hospital, Locked Bag 300 | Corner Grattan Street and Flemington Road, Parkville, VIC, 3052, Australia
Warner Huh, Division of Gynecologic Oncology, University of Alabama, 1700 6th Avenue South, Birmingham, AL, 35233, USA
Marc Steben, Département de médecine sociale et préventive, École de santé publique, Université de Montréal, 1851 East Sherbrooke Street, Montréal, Quebec, H2K 4L5, Canada
Cosette M. Wheeler, Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Comprehensive Cancer Center, 1201 Camino de Salud NE, Albuquerque, NM, 87102, USA.
Alfred Saah, Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA
Alain Luxembourg, Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA
Se Li, Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA
Christine Velicer, Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA

Document Type

Article

Publication Date

6-1-2022

Abstract

BACKGROUND: Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited.

METHODS: In this post hoc analysis of 3875 women aged 16-23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods.

RESULTS: Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%-3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16).

CONCLUSIONS: Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.

CLINICALTRIALS: gov; NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482.

Download

Share

COinS